The following supplements to The Oncologist are currently available online:

FULLTEXT

Assessing and Improving Value in Cancer Care

The Oncologist 15 (Suppl 1) : 1S-79S.

New Directions in the Therapeutic Strategy to Improve Survival Outcomes in Patients with Non-Hodgkin's Lymphoma

The Oncologist 14 (Suppl 2) : 1S-54S.

Twenty Years of Anemia Management with Erythropoiesis-Stimulating Agents (ESAs) in Nephrology and Oncology/Hematology

The Oncologist 14 (Suppl 1) : 1S-62S.

Evolving Role of CTLA-4 in Melanoma

The Oncologist 13 (Suppl 4) : 1S-25S.

The Future of Anemia Management for Cancer Patients with Chemotherapy-Related Anemia

The Oncologist 13 (Suppl 3) : 1S-36S.

The Role of Radiological Imaging in Assessing Clinical Benefit in Soft Tissue Sarcomas

The Oncologist 13 (Suppl 2) : 1S-40S.

Systemic Treatment for Advanced (Stage IIIb/IV) Non-Small Cell Lung Cancer: More Treatment Options; More Things to Consider

The Oncologist 13 (Suppl 1) : 1S-46S.

Innovative Advances in Treating Acute Myelogenous Leukemia and Associated Fungal Infections

The Oncologist 12 (Suppl 2) : 1S-26S.

Cancer-Related Fatigue: Causes, Consequences, and Management

The Oncologist 12 (Suppl 1) : 1S-67S.

Advances in the Treatment of Breast Cancer: Milestones in Management, Confidence in Care

The Oncologist 11 (Suppl 1) : 1S-51S.

Treatment Advances in Solid Tumors During the Past Decade: Benchmark Studies Impacting Survival and Quality of Life

The Oncologist 10 (Suppl 3) : 1S-58S.

Reaching for a Cure: New Horizons for Early Stage Neoplastic Disease

The Oncologist 10 (Suppl 2) : 1S-34S.

Bisphosphonates in Metastatic Bone Disease: Renal Safety Matters

The Oncologist 10 (Suppl 1) : 1S-24S.

New Horizons for Topotecan: Important Advances in the Treatment of Lung Cancer

The Oncologist 9 (Suppl 6) : 1S-52S.

Beyond Hemoglobin and Quality of Life: Exploring the Spectrum of Clinical Benefits with rHuEpo

The Oncologist 9 (Suppl 5) : 1S-73S.

Optimizing Bisphosphonate Therapy in Oncology

The Oncologist 9 (Suppl 4) : 1S-47S.

The Future of ErbB-1 and ErbB-2 Pathway Inhibition in Breast Cancer: Targeting Multiple Receptors

The Oncologist 9 (Suppl 3) : 1S-26S.

Microtubule Stabilization in the Treatment of Solid Tumors: Role of the Taxanes

The Oncologist 9 (Suppl 2) : 1S-32S.

Targeting VEGF in Cancer Treatment

The Oncologist 9 (Suppl 1) : 1S-49S.

Penetrating Insights: Crossing the Cancer Cell Membrane to Improve Clinical Outcomes

The Oncologist 8 (Suppl 3) : 1S-45S.

Liposomal Anthracyclines for Breast Cancer: Clinical Efficacy and Safety Update

The Oncologist 8 (Suppl 2) : 1S-30S.

Cancer Fatigue: The Way Forward

The Oncologist 8 (Suppl 1) : 1S-33S.

Incorporating Oral Capecitabine into the Treatment of Breast Cancer

The Oncologist 7 (Suppl 6) : 1S-35S.

Current Perspectives in the Treatment of Ovarian Cancer: An Update on the Role of Topotecan

The Oncologist 7 (Suppl 5) : 1S-55S.

ZD1839 (Iressa^TM): A New Targeted Therapy for Solid Tumors

The Oncologist 7 (Suppl 4) : 1S-39S.

Novel Molecular Targets for Cancer Therapy

The Oncologist 7 (Suppl 3) : 1S-41S.

Schwartz Center Rounds: Volume 1

The Oncologist 7 (Suppl 2) : 1S-65S.

Novel Approaches to the Treatment of Advanced Hematologic Malignancies

The Oncologist 7 (Suppl 1) : 1S-49S.

Targeted Drug Therapy: Hypomethylation, VEGF-R, and c-Mpl

The Oncologist 6 (Suppl 5) : 1S-39S.

Incorporating Oral Capecitabine into the Treatment of Colorectal Cancer

The Oncologist 6 (Suppl 4) : 1S-39S.

Innovative Therapies in Breast Cancer

The Oncologist 6 (Suppl 3) : 1S-44S.

Arsenic Trioxide: Scientific and Clinical Progress

The Oncologist 6 (Suppl 2) : 1S-32S.

New Directions in the Treatment of Non-Small Cell Lung Cancer

The Oncologist 6 (Suppl 1) : 1S-27S.

Radiation Therapy, Anemia, and Outcomes: Current Concepts, Future Strategies

The Oncologist 5 (Suppl 2) : 1S-23S.

Translational Research: The Role of VEGF in Tumor Angiogenesis

The Oncologist 5 (Suppl 1) : 1S-54S.

ABSTRACTS